JP2005527510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527510A5 JP2005527510A5 JP2003572598A JP2003572598A JP2005527510A5 JP 2005527510 A5 JP2005527510 A5 JP 2005527510A5 JP 2003572598 A JP2003572598 A JP 2003572598A JP 2003572598 A JP2003572598 A JP 2003572598A JP 2005527510 A5 JP2005527510 A5 JP 2005527510A5
- Authority
- JP
- Japan
- Prior art keywords
- type
- phosphodiesterase
- inhibitor
- phosphodiesterase inhibitor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36296902P | 2002-03-06 | 2002-03-06 | |
| US36262002P | 2002-03-07 | 2002-03-07 | |
| PCT/CA2003/000313 WO2003074082A1 (en) | 2002-03-06 | 2003-03-06 | Formulations and methods of using nitric oxide mimetics in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527510A JP2005527510A (ja) | 2005-09-15 |
| JP2005527510A5 true JP2005527510A5 (https=) | 2006-04-20 |
Family
ID=27791719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572598A Pending JP2005527510A (ja) | 2002-03-06 | 2003-03-06 | 癌の治療において一酸化窒素模倣体を使用するための製剤および方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1492567A1 (https=) |
| JP (1) | JP2005527510A (https=) |
| AU (1) | AU2003208228A1 (https=) |
| CA (1) | CA2478145A1 (https=) |
| WO (1) | WO2003074082A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| DE602005027461D1 (de) | 2004-04-21 | 2011-05-26 | Enobia Pharma Inc | Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen |
| US7329495B2 (en) | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
| WO2005120493A1 (en) * | 2004-06-10 | 2005-12-22 | Tohoku University | Anticancer effect enhancer |
| WO2006018088A1 (en) * | 2004-08-19 | 2006-02-23 | Switch Biotech Ag | Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders |
| ATE438403T1 (de) * | 2004-08-19 | 2009-08-15 | Switch Biotech Llc | Verwendung eines pde5-hemmers zur behandlung und vorbeugung von hypopigmentierungsstörungen |
| AU2012203798B2 (en) * | 2005-08-12 | 2013-11-07 | Northrop Grumman Systems Corporation | O-nitro compounds, pharmaceutical compositons thereof and uses thereof |
| US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
| WO2009086470A2 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
| JP5467259B2 (ja) * | 2008-03-13 | 2014-04-09 | 国立大学法人 千葉大学 | シスプラチン効果増強剤及び抗癌剤キット |
| AU2009244790B2 (en) * | 2008-05-09 | 2013-09-12 | Duke University | Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells |
| JP6055779B2 (ja) | 2010-12-27 | 2016-12-27 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ナトリウム利尿ペプチドを含む組成物およびその使用方法 |
| EP3189835B1 (en) * | 2011-02-28 | 2018-07-25 | National Cerebral and Cardiovascular Center | Medical agent for suppressing malignant tumor metastasis |
| JP5842367B2 (ja) * | 2011-04-07 | 2016-01-13 | ニプロ株式会社 | 抗癌剤増感剤 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| CN106572988B (zh) | 2014-04-08 | 2022-04-08 | 卫理公会医院 | Inos抑制性组合物及其作为乳腺癌治疗剂的用途 |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| JP6993961B2 (ja) | 2015-08-17 | 2022-01-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼの製造 |
| EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| KR20240160671A (ko) | 2016-04-01 | 2024-11-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타아제로 근육 약화의 치료 |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| EP3464573B1 (en) | 2016-06-06 | 2026-03-04 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| KR20190129058A (ko) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| ES2972119T3 (es) | 2018-08-10 | 2024-06-11 | Alexion Pharma Inc | Cicatrización ósea en implantes utilizando fosfatasa alcalina |
| KR20220111693A (ko) | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법 |
| US12083169B2 (en) | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CN114869894A (zh) * | 2022-05-10 | 2022-08-09 | 福州大学 | 一种小分子化合物在制备作为尿激酶受体抑制剂药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LV11542B (en) * | 1995-03-30 | 1997-02-20 | Latvijas Organiskas Sintezes Instituts | Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof |
| AU8398398A (en) * | 1997-07-14 | 1999-02-10 | Brigham And Women's Hospital | Modification of nitric oxide activity to treat fas-induced pathologies |
| JP2004508279A (ja) * | 2000-01-26 | 2004-03-18 | シーダース シナイ メディカル センター | 薬剤を異常脳領域及び／又は悪性腫瘍にデリバリーするためにカリウムチャンネル活性化を用いる方法 |
| US20010038832A1 (en) * | 2000-04-11 | 2001-11-08 | Benjamin Bonavida | Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity |
| JP2003531179A (ja) * | 2000-04-26 | 2003-10-21 | クイーンズ ユニバーシティ アット キングストン | 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法 |
-
2003
- 2003-03-06 JP JP2003572598A patent/JP2005527510A/ja active Pending
- 2003-03-06 AU AU2003208228A patent/AU2003208228A1/en not_active Abandoned
- 2003-03-06 WO PCT/CA2003/000313 patent/WO2003074082A1/en not_active Ceased
- 2003-03-06 EP EP03706181A patent/EP1492567A1/en not_active Withdrawn
- 2003-03-06 CA CA002478145A patent/CA2478145A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527510A5 (https=) | ||
| US6649645B1 (en) | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia | |
| US8202242B2 (en) | Method of using vasoconstrictive agents during energy-based tissue therapy | |
| KR101292508B1 (ko) | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 | |
| KR20060097000A (ko) | 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물 | |
| JP2009511450A (ja) | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ | |
| JP2013107893A (ja) | 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体 | |
| CA2606716C (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of systematic mastocytosis | |
| JP2009520787A (ja) | Ａｚｄ２１７１およびペメトレキセドの組み合わせ | |
| US12042499B2 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
| US7767686B2 (en) | Method of using adenosine receptor blockers during tissue ablation | |
| JP2005526821A (ja) | 癌の処置におけるグリベック（ｓｔｉ５７１）とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤 | |
| WO2002022127A1 (en) | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders | |
| JP2005255643A (ja) | 抗腫瘍効果増強方法および抗腫瘍効果増強剤 | |
| US20240173323A1 (en) | Combination therapy for cancer treatment | |
| JP5751568B2 (ja) | 悪性末梢神経鞘腫瘍の処置 | |
| AU2011202950B2 (en) | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia | |
| AU2004201161B2 (en) | Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia | |
| Saiko et al. | Heterodinucleoside phosphates of 5-fluorodeoxyuridine and arabinofuranosylcytosine-New drugs in cancer chemotherapy? | |
| JPH06107548A (ja) | 癌の肝転移抑制剤及び肝癌の治療剤 | |
| JP2013525296A (ja) | 内分泌療法抵抗性乳癌の処置 | |
| AU2013201915A1 (en) | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia | |
| JPWO2023083868A5 (https=) |